Last reviewed · How we verify
NCT04784390
Proof of Concept Study of Binocular Videogames Versus Patching for Amblyopia
Phase 1 trial testing Binocular video games in Amblyopia in 27 participants. Terminated before completion.
3 August 2022
Quick facts
| Lead sponsor | Novartis Pharmaceuticals |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 27 |
| Start date | 30 June 2021 |
| Primary completion | 3 August 2022 |
| Estimated completion | 3 August 2022 |
| Sites | 8 locations across Canada, United States, Australia |
Drugs / interventions tested
- Binocular video games
- Patching of the sound eye
Conditions studied
- Amblyopia — all drugs for Amblyopia →
Sponsor
Novartis Pharmaceuticals — full company profile →
Who can join
Adults 4 to 12, any sex, with Amblyopia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this PoC study was to evaluate the potential therapeutic efficacy of binocular video games played on a tablet and to compare the efficacy of binocular video games versus patching in amblyopic patients 4 to 7 years old (Part A) as well as to gain experience with binocular video games in older children population of 8 to12 years old (Part B). Part A and Part B was designed to provide long term data on durability of binocular video games treatment. The study consisted of two parts, Part A: randomized, single masked PoC study in children 4 to 7 years old at Screening, and Part B: open-label substudy in children 8 to 12 year old at Screening.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04784390
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Amblyopia
Currently open trials in the same condition.
- NCT07323953 — Evaluation of AmblyoFix for the Treatment of Unilateral Amblyopia in Children · NA · recruiting
- NCT07281742 — Amblyopia Treatment for Children Aged 8 to 12 Years · NA · recruiting
- NCT07417046 — Possible Beneficial Effects Of Combined Fluoxetine And Occlusion Therapy In Improving And Maintaining Vision In Amblyopi · NA · recruiting
- NCT06524882 — Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age · Phase 3 · recruiting
- NCT06380517 — Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age · Phase 3 · recruiting
Other Novartis Pharmaceuticals trials
Trials by the same sponsor.
- NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
- NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
- NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
- NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
- NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04784390 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
- Last refreshed: 23 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04784390.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing